Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: December 24, 2009
Last updated: July 27, 2014
Last verified: July 2014

This non-interventional study is to monitor use in real practice in Korea including adverse events on Aromasin (Exemestane).

Condition Intervention Phase
Breast Cancer
Drug: Aromasin
Phase 4

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • The nature, incidence, duration, and severity of adverse events; discontinuation due to adverse events; outcome and causality will be monitored in this study. [ Time Frame: adjuvant 1 year ; advanced 6 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Efficacy assessments based on objective tumor assessments according to the Response Evaluation Criteria in Solid Tumors(RECIST) of uni-dimensional evaluation. [ Time Frame: adjuvant 1 year ; advanced 6 years ] [ Designated as safety issue: No ]

Enrollment: 214
Study Start Date: August 2010
Study Completion Date: June 2014
Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
ajuvant group
adjuvant setting after two to three years of tamoxifen
Drug: Aromasin
25 mg table QD
Other Name: exemestane
palliative group
palliative setting after progression of disease with anti-estrogen therapy
Drug: Aromasin
25 mg table QD
Other Name: exemestane

Detailed Description:

All cases at the participating institutions.


Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

- Postmenopausal women diagnosed as estrogen-receptor positive early breast cancer, who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy OR postmenopausal women with breast cancer that has progressed following anti-estrogen therapy.


Inclusion Criteria:

  • Postmenopausal women with breast cancer eligible for hormonal therapy.

Exclusion Criteria:

  • Pregnant breast-feeding premenopausal.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01047358

Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer Identifier: NCT01047358     History of Changes
Other Study ID Numbers: A5991089
Study First Received: December 24, 2009
Last Updated: July 27, 2014
Health Authority: Korea: Food and Drug Administration

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms by Site
Skin Diseases
Antineoplastic Agents
Aromatase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on May 21, 2015